YAP1 and triple-A syndrome: Indeed, our study confirmed that AF transformation and migration involved in AAA lesions, which may be facilitated by YAP1; in vivo study showed that YAP1 inhibitor‐Verteporfin diminished AF transformation to myofibroblast and migration; in vitro study proved furtherly that YAP1 inhibitor‐verteporfin remarkably attenuated the process of AF transformed to myofibroblast by inhibiting α‐SMA expression and migration demonstrated by wound healing experiment.